Clinical Trial Update: A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer [Phase 2]

View source ↗

Summary

Phase II study evaluating serplulimab plus bevacizumab with chemotherapy as first-line treatment for untreated recurrent or metastatic cervical cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Serplulimab (serplulimab)

Snippet

Sponsor: Sichuan Cancer Hospital and Research Institute | Conditions: Cervical Cancer | Phase 2 | Status: UNKNOWN